# FDA 483 - Boehringer Ingelheim Biopharmaceuticals (China) Ltd. - June 09, 2023

Source: https://www.globalkeysolutions.net/records/483/boehringer-ingelheim-biopharmaceuticals-china-ltd/043bec50-de87-4e6d-a9d9-e057770f067b

> FDA 483 for Boehringer Ingelheim Biopharmaceuticals (China) Ltd. on June 09, 2023. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Boehringer Ingelheim Biopharmaceuticals (China) Ltd.
- Inspection Date: 2023-06-09
- Product Type: drugs
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)

## Related Officers

- [Yiwei Li, Ph.D., Supervisory Chemist](https://www.globalkeysolutions.net/people/yiwei-li-phd-supervisory-chemist/25391f15-b3ee-400e-9e10-4fc2b674facc)
- [Leiyun Boone, PhD, Lead Biologist](https://www.globalkeysolutions.net/people/leiyun-boone-phd-lead-biologist/bff36082-6e40-4d97-b452-8b89d415e5be)
- [Zhong Li, Ph.D., Sr. Pharmaceutical Quality Assessor](https://www.globalkeysolutions.net/people/zhong-li-phd-sr-pharmaceutical-quality-assessor/cdc177bb-92f6-4d53-ba84-6e878c68917a)

Company: https://www.globalkeysolutions.net/companies/boehringer-ingelheim-biopharmaceuticals-china-ltd/be450a8b-4f71-4f06-96b3-908a2ed1b580

Office: https://www.globalkeysolutions.net/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd